These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15156499)

  • 1. Persistence of HIV drug resistance mutations: more clues from clinical observations.
    Jenny-Avital ER; Stein DK
    Clin Infect Dis; 2004 May; 38(10):1507-8. PubMed ID: 15156499
    [No Abstract]   [Full Text] [Related]  

  • 2. Low-abundance drug resistance mutations: extending the HIV paradigm to hepatitis B virus.
    Menzo S; Vincenti D; Solmone M; Prosperi M; Bruselles A; Abbate I; Rozera G; Capobianchi MR
    J Infect Dis; 2009 Dec; 200(11):1798-9; author reply 1799-1800. PubMed ID: 19905934
    [No Abstract]   [Full Text] [Related]  

  • 3. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV-resistance evolution requires new strategies. Mutation risk higher if HIV RNA increases.
    AIDS Alert; 2005 Jan; 20(1):3. PubMed ID: 15717352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits of HIV resistance testing in optimizing drug discovery.
    Heilek-Snyder G; Bean P
    Am Clin Lab; 2002 Oct; 21(8):13-4. PubMed ID: 12440169
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
    Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow accumulation of HIV resistance mutations: implications for resource-limited settings?
    Stevens WS
    J Infect Dis; 2009 Sep; 200(5):670-2. PubMed ID: 19604045
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
    Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
    J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV drug resistance and you. Resistance overview. A look at the basics.
    Munk B
    Posit Aware; 2006; Spec No():6-9. PubMed ID: 16583502
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand.
    Apisarnthanarak A; Mundy LM
    Clin Infect Dis; 2008 May; 46(10):1630-1. PubMed ID: 18419506
    [No Abstract]   [Full Text] [Related]  

  • 12. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical data marshalled to treat HIV.
    Clarke T
    Nature; 2003 Jun; 423(6942):791. PubMed ID: 12815390
    [No Abstract]   [Full Text] [Related]  

  • 14. The K65R mutation: selection, frequency, and possible consequences.
    Moyle GJ
    AIDS Read; 2004 Nov; 14(11):595-7, 601-3. PubMed ID: 15570671
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV/AIDS. Tangled patent dispute over 'free' drug-resistance database.
    Cohen J
    Science; 2009 Feb; 323(5918):1156-7. PubMed ID: 19251598
    [No Abstract]   [Full Text] [Related]  

  • 16. Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough.
    Baraboutis IG; Papastamopoulos V; Georgiou O; Skoutelis AT
    Int J STD AIDS; 2007 Oct; 18(10):722-4. PubMed ID: 17945056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype testing for all HIV patients, study suggests. Resistance is 18 percent overall.
    AIDS Alert; 2007 Feb; 22(2):17-8. PubMed ID: 17763545
    [No Abstract]   [Full Text] [Related]  

  • 18. Accommodating uncertainty in a tree set for function estimation.
    Healy BC; DeGruttola VG; Hu C
    Stat Appl Genet Mol Biol; 2008; 7(1):Article5. PubMed ID: 18312210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children.
    Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Giraudi V; Ayala SG; Salomón H
    Antivir Ther; 2007; 12(7):1133-7. PubMed ID: 18018772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.
    Detsika MG; Chandler B; Khoo SH; Winstanley C; Cane P; Back DJ; Owen A
    J Antimicrob Chemother; 2007 Oct; 60(4):881-4. PubMed ID: 17650515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.